Emergo Therapeutics

Focus: Emergo Therapeutics is a biotechnology company focused on inflammation modification within immunology, headquartered in Durham, NC since 2016. The company operates at an early-stage development phase with limited public visibility on scale.

Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Emergo Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Emergo Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Left Ventricular Assist System

Advanced Refractory Left Ventricular Heart Failure

N/A

Clinical Trials (1)

NCT02170363HeartMate 3™ CE Mark Clinical Investigation Plan

N/A

Help build intelligence for Emergo Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic area (inflammation modification) offers deep specialization opportunity in a growing immunology space
Early-stage Durham location provides potential for equity upside and foundational role-building
Eight-year-old company has survived initial runway, suggesting some validation of scientific approach

Watch Out For

Zero active clinical trials reported suggests minimal near-term catalysts or potentially stalled pipeline development
No current job openings, no disclosed funding, and no revenue indicate possible dormancy or severe capital constraints
Lack of published data, news, or clinical activity creates transparency risk and uncertain competitive positioning

Generated by Claude from Emergo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Norketotifen Oral Capsule

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03712163Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects

Phase 1

Norketotifen

Allergic Rhinitis

Phase 2

Clinical Trials (1)

NCT03887026Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

Phase 2